Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back
Raise money when you can, not when you must — the common refrain rang loud in two IPO filings late Friday as ADC Therapeutics and Frequency Therapeutics looked to top up their recent raises with mega IPOs.
But when you can’t, as Dermavant found after a second try, then quitting might be imperative.
ADC and Frequency were joined by little cancer biotech Aprea Therapeutics, seeking a collective $336 million from Wall Street.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.